logo-loader
ImmunoPrecise Antibodies Ltd

ImmunoPrecise subsidiary U-Protein Express clinches license from Stanford University to manufacture protein

Wnt proteins are involved in signaling cells to divide and develop and the Wnt surrogate can be used as a growth factor in cell culture for the growing of organoids

cells
ImmunoPrecise is an antibody discovery company, which offers an array of antibody services from target analysis to pre-clinical studies

U-Protein Express, an ImmunoPrecise Antibodies Ltd subsidiary in Utrech, Netherlands, has won a victory after clinching an exclusive license from Stanford University to manufacture and sell a novel protein - Wnt surrogate Fc, a substitute for a protein known as Wnt.

Wnt proteins are involved in signaling cells to divide and develop and the Wnt surrogate can be used as a growth factor in cell culture for the growing of organoids.

READ: ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business

The exclusive nature of the awarded license ensures that U-Protein is the single, global manufacturer and supplier to offer the Wnt surrogate Fc to the market.

“The surrogate can be used not only as a growth factor in cell culture media for the growing of organoids but also with other cell lines,” ImmunoPrecise said in its release. “With hundreds of research groups around the world culturing organoids, the market for the Wnt surrogate Fc is strong.”

ImmunoPrecise is an antibody discovery company, which offers an array of antibody services from target analysis to pre-clinical studies.

The company operates from laboratory facilities located in Victoria, British Columbia, in collaboration with its wholly-owned subsidiaries -- U-Protein Express B.V. and ModiQuest Research, Oss, which are both in the Netherlands.

Contact Ellen Kelleher at [email protected]

 

Quick facts: ImmunoPrecise Antibodies Ltd

Price: $0.65

Market: TSX-V
Market Cap: $43.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 2/4/19

2 min read